| scholarly article | Q13442814 |
| P50 | author | Marjolein van Egmond | Q30331995 |
| Richard J. Pleass | Q41823989 | ||
| Cees van Kooten | Q47158440 | ||
| Stephen Challacombe | Q57338922 | ||
| P2093 | author name string | Jenny M Woof | |
| Juraj Ivanyi | |||
| Melanie J Lewis | |||
| Rajko Reljic | |||
| Richard McIntosh | |||
| Sucharitha Balu | |||
| P2860 | cites work | Mycobacterium tuberculosis in the Extracellular Compartment: an Underestimated Adversary | Q22242240 |
| Identification of residues in the CH2/CH3 domain interface of IgA essential for interaction with the human fcalpha receptor (FcalphaR) CD89 | Q28141479 | ||
| The Fc receptor for IgA (FcalphaRI, CD89) | Q28256169 | ||
| Antibody arrays for high-throughput screening of antibody-antigen interactions | Q30918339 | ||
| A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival | Q33606785 | ||
| Assessment of immunity to mycobacterial infection with luciferase reporter constructs. | Q34001753 | ||
| Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice | Q34033996 | ||
| Identification of FcalphaRI as an inhibitory receptor that controls inflammation: dual role of FcRgamma ITAM. | Q34386917 | ||
| Antibody-mediated immunity against intracellular pathogens: two-dimensional thinking comes full circle | Q35182322 | ||
| Tuberculosis control in the era of HIV. | Q36274930 | ||
| Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger's disease). Evidence for pathogenic soluble receptor-Iga complexes in patients and CD89 transgenic mice | Q36404662 | ||
| Mucosal immunotherapy of tuberculosis: is there a value in passive IgA? | Q36410732 | ||
| Confronting the scientific obstacles to global control of tuberculosis | Q36513366 | ||
| An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries | Q36850688 | ||
| Functional and clinical consequences of Fc receptor polymorphic and copy number variants. | Q37552028 | ||
| Role of IgA and IgA fc receptors in inflammation | Q37616061 | ||
| A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab') fragment prolong survival of mice infected with Mycobacterium tuberculosis | Q38336530 | ||
| Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis | Q39468908 | ||
| Prevention of the post-chemotherapy relapse of tuberculous infection by combined immunotherapy. | Q40029818 | ||
| FcalphaRI (CD89) alleles determine the proinflammatory potential of serum IgA. | Q40162956 | ||
| The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. | Q40793082 | ||
| Time course of mycobacterial infection of dendritic cells in the lungs of intranasally infected mice | Q44957567 | ||
| Antibodies: basic mechanisms and emerging concepts. | Q46038519 | ||
| Antibody bound to the surface antigen MPB83 of Mycobacterium bovis enhances survival against high dose and low dose challenge | Q47600118 | ||
| Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. | Q47980043 | ||
| Prophylactic effect of administration of human gamma globulins in a mouse model of tuberculosis. | Q48016568 | ||
| Evaluation of Human Antimycobacterial Immunity Using Recombinant Reporter Mycobacteria | Q59632141 | ||
| Induction of a protective response with an IgA monoclonal antibody against Mycobacterium tuberculosis 16kDa protein in a model of progressive pulmonary infection | Q63253484 | ||
| Recessive expression of the H2A-controlled immune response phenotype depends critically on antigen dose | Q73486503 | ||
| Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins | Q77530423 | ||
| The human Fc receptor for IgA (Fc alpha RI, CD89) on transgenic peritoneal macrophages triggers phagocytosis and tumor cell lysis | Q77972799 | ||
| IL-4 depletion enhances host resistance and passive IgA protection against tuberculosis infection in BALB/c mice | Q79784864 | ||
| Injection of recombinant FcalphaRI/CD89 in mice does not induce mesangial IgA deposition | Q80512829 | ||
| Intranasal IFNgamma extends passive IgA antibody protection of mice against Mycobacterium tuberculosis lung infection | Q82599395 | ||
| Passive serum therapy with polyclonal antibodies against Mycobacterium tuberculosis protects against post-chemotherapy relapse of tuberculosis infection in SCID mice | Q83347663 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tuberculosis | Q12204 |
| antibody | Q79460 | ||
| monoclonal antibody | Q422248 | ||
| P304 | page(s) | 3113-3119 | |
| P577 | publication date | 2011-01-21 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | A novel human IgA monoclonal antibody protects against tuberculosis | |
| P478 | volume | 186 |
| Q64260919 | A Case for Antibodies as Mechanistic Correlates of Immunity in Tuberculosis |
| Q39352413 | A Functional Role for Antibodies in Tuberculosis |
| Q42370800 | A baculovirus-conjugated mimotope vaccine targeting Mycobacterium tuberculosis lipoarabinomannan |
| Q92636834 | Alternative Vaccination Routes against Paratuberculosis Modulate Local Immune Response and Interference with Tuberculosis Diagnosis in Laboratory Animal Models |
| Q92538491 | An Inflammatory Story: Antibodies in Tuberculosis Comorbidities |
| Q38041566 | An update on vaccines for tuberculosis - there is more to it than just waning of BCG efficacy with time |
| Q36366594 | Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells. |
| Q28067735 | Antibodies and tuberculosis |
| Q89001788 | Antibodies and tuberculosis: finally coming of age? |
| Q37137882 | Antibody-mediated immunity against tuberculosis: implications for vaccine development |
| Q36238031 | B cells and antibodies in the defense against Mycobacterium tuberculosis infection |
| Q91316102 | B lymphocytes in anti-mycobacterial immune responses: Pathogenesis or protection? |
| Q39002020 | B lymphocytes that migrate to tuberculous pleural fluid via the SDF-1/CXCR4 axis actively respond to antigens specific for Mycobacterium tuberculosis |
| Q40382208 | B-lymphocytes forming follicle-like structures in the lung tissue of tuberculosis-infected mice: Dynamics, phenotypes and functional activity. |
| Q40086314 | Bolstering Immunity through Pattern Recognition Receptors: A Unique Approach to Control Tuberculosis |
| Q37955274 | Bovine paratuberculosis: recent advances in vaccine development |
| Q41684142 | Cellular Architecture of Spinal Granulomas and the Immunological Response in Tuberculosis Patients Coinfected with HIV. |
| Q35996521 | Cellular and humoral mechanisms involved in the control of tuberculosis |
| Q63253476 | Comparative study of IgA VH 3 gene usage in healthy TST(-) and TST(+) population exposed to tuberculosis: deep sequencing analysis |
| Q50567743 | Developing aerosol vaccines for Mycobacterium tuberculosis: Workshop proceedings: National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA, April 9, 2014. |
| Q38262258 | Development of a new tuberculosis vaccine: is there value in the mucosal approach? |
| Q39961868 | Development of an effective delivery system for intranasal immunization against Mycobacterium tuberculosis ESAT-6 antigen |
| Q39197564 | Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance |
| Q36500269 | Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens |
| Q59798720 | Dual-Isotope SPECT/CT Imaging of the Tuberculosis Subunit Vaccine H56/CAF01: Induction of Strong Systemic and Mucosal IgA and T-Cell Responses in Mice Upon Subcutaneous Prime and Intrapulmonary Boost Immunization |
| Q90004714 | Emerging Themes for the Role of Antibodies in Tuberculosis |
| Q43838346 | Enhanced protection against pulmonary mycobacterial challenge by chitosan-formulated polyepitope gene vaccine is associated with increased pulmonary secretory IgA and gamma-interferon(+) T cell responses |
| Q36216363 | Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding |
| Q36237421 | Evaluation of Humoral Immunity to Mycobacterium tuberculosis-Specific Antigens for Correlation with Clinical Status and Effective Vaccine Development. |
| Q38029985 | Fc-fusion proteins: new developments and future perspectives. |
| Q38203257 | Function and Potentials of M. tuberculosis Epitopes |
| Q35929062 | Functional flexibility of intestinal IgA - broadening the fine line |
| Q52332235 | Glycosylation of Human IgA Directly Inhibits Influenza A and Other Sialic-Acid-Binding Viruses. |
| Q34178105 | Histopathological Study of the Lungs of Mice Receiving Human Secretory IgA and Challenged with Mycobacterium tuberculosis |
| Q45006012 | Host-Directed Therapeutic Strategies for Tuberculosis |
| Q41704272 | Human Cell Line-Derived Monoclonal IgA Antibodies for Cancer Immunotherapy |
| Q39301694 | Human isotype-dependent inhibitory antibody responses against Mycobacterium tuberculosis |
| Q64060912 | IgA and FcαRI: Pathological Roles and Therapeutic Opportunities |
| Q91811769 | IgA: Structure, Function, and Developability |
| Q47135299 | Immunity to α-Gal: The Opportunity for Malaria and Tuberculosis Control. |
| Q51602972 | Immunization with Single Oral Dose of Alginate-Encapsulated BCG Elicits Effective and Long-Lasting Mucosal Immune Responses. |
| Q36927153 | Immunogenicity of mycobacterial vesicles in humans: identification of a new tuberculosis antibody biomarker |
| Q37892323 | Immunoglobulin A: A next generation of therapeutic antibodies? |
| Q56911915 | Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection |
| Q26741261 | Immunotherapy for tuberculosis: future prospects |
| Q36487349 | Impact of IgA constant domain on HIV-1 neutralizing function of monoclonal antibody F425A1g8. |
| Q43177854 | Insights from Fc receptor biology: a route to improved antibody reagents |
| Q38620366 | Integrating knowledge of Mycobacterium tuberculosis pathogenesis for the design of better vaccines |
| Q35312084 | Interaction of human, rat, and mouse immunoglobulin A (IgA) with Staphylococcal superantigen-like 7 (SSL7) decoy protein and leukocyte IgA receptor |
| Q33719289 | Latently and uninfected healthcare workers exposed to TB make protective antibodies against Mycobacterium tuberculosis |
| Q90401072 | Lipoarabinomannan in Active and Passive Protection Against Tuberculosis |
| Q34512334 | Long-lived memory B-cell responses following BCG vaccination |
| Q52338712 | Mucosal Delivery of Fusion Proteins with Bacillus subtilis Spores Enhances Protection against Tuberculosis by Bacillus Calmette-Guérin. |
| Q42256538 | Mucosal delivery of antigen-coated nanoparticles to lungs confers protective immunity against tuberculosis infection in mice |
| Q92246549 | Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges |
| Q40868823 | Naturally produced opsonizing antibodies restrict the survival of Mycobacterium tuberculosis in human macrophages by augmenting phagosome maturation |
| Q35249355 | Principles and application of antibody libraries for infectious diseases. |
| Q30361227 | Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review. |
| Q104569038 | RTS,S/AS01E malaria vaccine induces IgA responses against CSP and vaccine-unrelated antigens in African children in the phase 3 trial |
| Q93061315 | Reassessing therapeutic antibodies for neglected and tropical diseases |
| Q38696320 | Relevance of bovine tuberculosis research to the understanding of human disease: historical perspectives, approaches, and immunologic mechanisms |
| Q35164284 | Role of B cells and antibodies in acquired immunity against Mycobacterium tuberculosis |
| Q37936765 | Structure and function relationships in IgA. |
| Q40346189 | Superior protection elicited by live-attenuated vaccines in the murine model of paratuberculosis. |
| Q93062702 | The Humoral Immune Response to BCG Vaccination |
| Q34499286 | The era of the immunoglobulin A Fc receptor FcαRI; its function and potential as target in disease |
| Q33968915 | The generation and evaluation of recombinant human IgA specific for Plasmodium falciparum merozoite surface protein 1-19 (PfMSP1 19). |
| Q33740190 | The human antibody response to the surface of Mycobacterium tuberculosis |
| Q34218284 | The human immunoglobulin A Fc receptor FcαRI: a multifaceted regulator of mucosal immunity |
| Q103760781 | Tuberculosis vaccination needs to avoid 'decoy' immune reactions |
| Q92857461 | Tuberculosis vaccine candidates based on mycobacterial cell envelope components |
| Q37156509 | Vaccination sequence effects on immunological response and tissue bacterial burden in paratuberculosis infection in a rabbit model. |
| Q38286947 | Vaccines to prevent tuberculosis infection rather than disease: Physiological and immunological aspects |
Search more.